Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade

Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade

Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment providing unprecedented clinical benefits. However, many patients do not respond to ICIs as monotherapy or develop resistance. Combining ICI-based immunotherapy with chemotherapy is a promising strategy to inc...

Full description

Bibliographic Details
Main Authors: Alessandra Rossi, Valeria Lucarini, Iole Macchia, Paola Sestili, Carla Buccione, Simona Donati, Maria Ciccolella, Antonella Sistigu, Maria Teresa D’Urso, Anna Maria Pacca, Enrico Cardarelli, Fabrizio Mattei, Enrico Proietti, Giovanna Schiavoni, Laura Bracci
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cells
Subjects:
programmed death ligand
chemotherapy
mouse models
chemo-immunotherapy
immune response
myeloid infiltrate
Online Access:https://www.mdpi.com/2073-4409/9/4/940

Internet

https://www.mdpi.com/2073-4409/9/4/940

Similar Items